Zocor Manufacturing Efficiencies Reduce Cycle Times By 30%
Executive Summary
Merck has reduced Zocor manufacturing cycle times by 30% since 2000 through process improvements and enhanced supply chain management, Manufacturing Division President Richard Clark told analysts
You may also be interested in...
Merck Sees Strong Cholesterol Market In ‘04; Zocor Growth, Profit From Zetia
Merck expects Zocor sales to remain in the $5 bil. range in 2004 despite generic erosion overseas and the introduction of new competitors in the cholesterol class
Big Pharma “Cost Structure” Needs Attention, Lilly CEO Says
The pharmaceutical industry needs to make significant changes to its cost structure to remain competitive over the next three to five years, Lilly CEO Sidney Taurel said
Zocor Sales To Take $500 Mil. Hit In 2003 From Merck Inventory Program
Merck's change in inventory management practices will reduce Zocor sales in 2003 by $500 mil